RoxyBond Clears US FDA With Abuse-Deterrent Properties, But No REMS Yet
Executive Summary
Inspirion's oxycodone is first immediate-release opioid approved with abuse-deterrent language in labeling.
You may also be interested in...
Not Your Typical Response: Oxycodone Sponsor Seeks FDA Hearing On Complete Response Letter
Data on abuse deterrence for Pharmaceutical Manufacturing Research Services' oxycodone immediate-release product are insufficient, FDA tells company.
Keeping Track: Biosimilar Submissions Galore (And An Approval), Bayer Gets An Oncology Approval, KemPharm Resubmits Apadaz NDA
The latest regulatory submission news and highlights from our US FDA Performance Tracker.
Keeping Track: Breakthroughs Dominate 2017 Novel Agents; US FDA Approves Rydapt, Alunbrig, Tymlos, Brineura
The latest drug development news and highlights from our FDA Performance Tracker.